- AstraZeneca Plc AZN and Daiichi Sankyo DSNKY DSKYF shared updated data from the DESTINY-Breast03 Phase 3 trial evaluating Enhertu versus trastuzumab emtansine (T-DM1) in previously treated patients with HER2-positive unresectable and/or metastatic breast cancer.
- Enhertu demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to T-DM1.
- In the key secondary endpoint analysis of overall survival for DESTINY-Breast03, Enhertu demonstrated a 36% reduction in risk of death versus T-DM1.
- In both treatment arms, median OS was not yet reached after a median duration of follow-up of 28.4 months for Enhertu and 26.5 months for T-DM1.
- An estimated 77.4% of patients were alive in the Enhertu arm at two years, compared to 69.9% of patients treated with T-DM1.
- With the additional follow-up in DESTINY-Breast03, Enhertu also demonstrated a clinically meaningful improvement in progression-free survival (PFS) with a 22-month improvement in median PFS over T-DM1, reaffirming the statistically significant finding at the previous interim analysis.
- In primary results from the DESTINY-Breast02 Phase 3 trial, Enhertu demonstrated a 64% reduction in the risk of disease progression or death in patients.
- The median PFS for patients in the Enhertu arm was 17.8 months versus 6.9 months for those in the physician’s choice of treatment arm.
- Enhertu also showed a 34% reduction in the risk of death compared to the physician’s treatment choice, with a median OS of 39.2 months versus 26.5 months.
- Price Action: AZN shares are down 0.03% at $68.54 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.